4//SEC Filing
venBio Global Strategic Fund II L.P. 4
Accession 0000905148-20-000880
CIK 0001651431other
Filed
Aug 11, 8:00 PM ET
Accepted
Aug 12, 9:00 PM ET
Size
19.5 KB
Accession
0000905148-20-000880
Insider Transaction Report
Form 4
venBio Global Strategic Fund II L.P.
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total→ Common Stock (1,671,771 underlying) - Conversion
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total→ Common Stock (487,438 underlying) - Conversion
Common Stock
2020-08-11+3,473,374→ 3,473,374 total - Purchase
Common Stock
2020-08-11$15.00/sh+200,000$3,000,000→ 3,673,374 total - Conversion
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total→ Common Stock (1,314,165 underlying)
venBio Global Strategic GP II, L.P.
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total→ Common Stock (1,671,771 underlying) - Conversion
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total→ Common Stock (1,314,165 underlying) - Conversion
Common Stock
2020-08-11+3,473,374→ 3,473,374 total - Conversion
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total→ Common Stock (487,438 underlying) - Purchase
Common Stock
2020-08-11$15.00/sh+200,000$3,000,000→ 3,673,374 total
venBio Global Strategic GP II, Ltd.
10% Owner
Transactions
- Conversion
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total→ Common Stock (1,671,771 underlying) - Conversion
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total→ Common Stock (1,314,165 underlying) - Purchase
Common Stock
2020-08-11$15.00/sh+200,000$3,000,000→ 3,673,374 total - Conversion
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total→ Common Stock (487,438 underlying) - Conversion
Common Stock
2020-08-11+3,473,374→ 3,473,374 total
GOODMAN COREY S
10% Owner
Transactions
- Conversion
Common Stock
2020-08-11+3,473,374→ 3,473,374 total - Conversion
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total→ Common Stock (1,671,771 underlying) - Conversion
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total→ Common Stock (487,438 underlying) - Purchase
Common Stock
2020-08-11$15.00/sh+200,000$3,000,000→ 3,673,374 total - Conversion
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total→ Common Stock (1,314,165 underlying)
Adelman Robert J
10% Owner
Transactions
- Purchase
Common Stock
2020-08-11$15.00/sh+200,000$3,000,000→ 3,673,374 total - Conversion
Series B Preferred Stock
2020-08-11−8,753,350→ 0 total→ Common Stock (1,314,165 underlying) - Conversion
Series C Preferred Stock
2020-08-11−3,644,624→ 0 total→ Common Stock (487,438 underlying) - Conversion
Common Stock
2020-08-11+3,473,374→ 3,473,374 total - Conversion
Series A Preferred Stock
2020-08-11−12,500,000→ 0 total→ Common Stock (1,671,771 underlying)
Footnotes (3)
- [F1]The Series A Preferred Stock and Series C Preferred Stock automatically converted into Common Stock at a rate of 1:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F2]The Series B Preferred Stock automatically converted into Common Stock at a rate of 1.12256:7.4771 upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- [F3]The shares are held by venBio Global Strategic Fund II, L.P. venBio Global Strategic GP II, L.P. is the sole general partner of venBio Global Strategic Fund II, L.P. and venBio Global Strategic GP II, Ltd. is the sole general partner of venBio Global Strategic GP II, L.P. Each of Corey Goodman and Robert Adelman is a director of venBio Global Strategic GP II, Ltd. Each of venBio Global Strategic GP II, L.P., venBio Global Strategic GP II, Ltd., Dr. Goodman and Dr. Adelman disclaims beneficial ownership of such securities, except to the extent of its/his indirect pecuniary interest therein.
Documents
Issuer
Checkmate Pharmaceuticals, Inc.
CIK 0001651431
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001634632
Filing Metadata
- Form type
- 4
- Filed
- Aug 11, 8:00 PM ET
- Accepted
- Aug 12, 9:00 PM ET
- Size
- 19.5 KB